ArticleFrontiers in immunology2026
Calculated globulin as a surrogate marker for hypogammaglobulinemia: establishing clinical decision limits in a Brazilian population cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inborn errors of immunity (formerly primary immunodeficiencies) encompass a group of genetic disorders characterized by defects in innate and/or adaptive immunity. Serum Immunoglobulin G (IgG) quantification is the diagnostic gold standard for hypogammaglobulinemia, but it is not routinely ordered in general clinical practice. Calculated globulin (CG) has been proposed as a potential surrogate marker. The current study aimed to evaluate the association between CG levels and adverse clinical outcomes and to propose CG-based clinical decision thresholds relevant to a cohort of Brazilian population. Methods: A cross-sectional analysis of longitudinal records was conducted encompassing CG measurements from 50, 539 individuals aged ≥1 year. Odds ratios (OR) and probability curves were calculated using predefined CG cut-off points (0.5 to 2.1 g/dL). Results: Linear regression analysis demonstrated a linear association between CG and IgG levels, described by the equation IgG = 0.523 × CG - 0.33. Lower CG levels were associated with increased risk of mortality, hospitalization, ICU admission, emergency care utilization, and higher frequency of antibiotic use. A CG threshold of ≤2.0- 2.1 g/dL was associated with a higher risk of adverse outcomes. Discussion: CG is a widely available, low-cost parameter with potential utility as a screening tool for primary or secundary antibody deficiencies. Clinical decision thresholds for hypogammaglobulinemia appear to be higher than the lower reference limits currently used in Brazilian laboratories. These findings highlight the need for revised clinical decision limits tailored to specific populations and support the integration of CG into routine screening strategies for earlier detection of antibody deficiencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.